Clinical Trials Sponsored by Sirtris, a GSK Company

Total 105 results

Sirtris, a GSK Company
GlaxoSmithKline

Terminated

A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma

Multiple Myeloma

United Kingdom, Denmark
Sirtris, a GSK Company
GlaxoSmithKline

Completed

Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects

Diabetes Mellitus, Type 2

Bulgaria, Estonia, Russian Federation, Ukraine, United Kingdom, Hungary, Poland, Romania
Sirtris, a GSK Company

Completed

A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases

Diabetes Mellitus, Type 2

United Kingdom
Sirtris, a GSK Company
GlaxoSmithKline

Completed

Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation

Sepsis

Netherlands
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases

Neoplasms, Colorectal

United Kingdom
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects

Diabetes Mellitus, Type 2

United Kingdom
Sirtris, a GSK Company
GlaxoSmithKline

Completed

Effect of SRT2379 on Endotoxin-Induced Inflammation

Sepsis

Netherlands
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United Kingdom
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers

Diabetes Mellitus, Type 2 | Healthy Volunteer

United Kingdom
Sirtris, a GSK Company
GlaxoSmithKline

Completed

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

Psoriasis

United States
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers

Diabetes Mellitus, Type 2

United Kingdom
Sirtris, a GSK Company

Completed

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

Psoriasis

United States
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

Colitis, Ulcerative

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.

Dermatitis, Chronic

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

Hyperhidrosis

United States, Canada
Stiefel, a GSK Company
GlaxoSmithKline

Completed

U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne

Acne Vulgaris
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam

Psoriasis

United States
Stiefel, a GSK Company

Completed

U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™

Acne Vulgaris
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule

Onychomycosis

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus

Onychomycosis

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications

Acne Vulgaris

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne

Acne

United States
Stiefel, a GSK Company

Completed

8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne

Acne Vulgaris
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.

Onychomycosis

United States, South Africa, Canada, Dominican Republic, Ecuador, Honduras, Panama
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301

Acne Vulgaris

United States, Canada
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications

Acne Vulgaris

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne

Acne Vulgaris

Spain
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Study to Assess Blood Levels of Itraconazole During a Two-Week Period

Healthy

United States
Stiefel, a GSK Company

Completed

An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne

Acne

Belgium, Netherlands
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis

Onychomycosis

United States, Canada, Iceland
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris

Acne Vulgaris

Germany
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers

Acne Vulgaris

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers

Acne Vulgaris

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris

Acne Vulgaris

Poland, United Kingdom
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)

Tinea Pedis

United States, Australia
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash

Acne Vulgaris

United States
Stiefel, a GSK Company

Completed

A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

Dermatitis, Atopic

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications

Acne Vulgaris

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

Acne Vulgaris

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris (C0000-411)

Acne Vulgaris
Stiefel, a GSK Company
GlaxoSmithKline

Completed

The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis

Psoriasis

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne

Acne Vulgaris

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis

Plaque-Type Psoriasis

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants

Diaper Rash

United States, Dominican Republic, Ecuador, Panama
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia

Alopecia

Korea, Republic of, Taiwan, Singapore, Hong Kong, Chile
Stiefel, a GSK Company
GlaxoSmithKline

Completed

Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis

Psoriasis

Russian Federation, Ireland, Germany, Netherlands, United Kingdom
Stiefel, a GSK Company
GlaxoSmithKline

Completed

W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers

Acne Vulgaris
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

Acne Vulgaris

United States
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

Acne Vulgaris

United States
Stiefel, a GSK Company

Completed

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

Psoriasis

United States, Germany

3

Subscribe